Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabTreatment
NCT00096512S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment